Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.99 USD
+0.05 (1.27%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 5:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Aquestive Therapeutics, Inc. has a market cap of $391.35M, which represents its share price of $3.94 multiplied by its outstanding shares number of 99.33M. As a small-cap company, AQST's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AQST 3.99 +0.05(1.27%)
Will AQST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Other News for AQST
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business ...
Commit To Buy Aquestive Therapeutics At $2.50, Earn 32.4% Annualized Using Options
Aquestive Therapeutics (AQST) Appoints New Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer